kt 6149 has been researched along with Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ardiet, C; Catimel, G; De Bruijn, E; Dirix, L; Tranchand, B; Van Oosterom, A; Verdonk, R | 1 |
| Abe, O; Arisawa, Y; Inada, T; Inoue, S; Ishibiki, K; Kodaira, S; Kubota, T; Kuzuoka, M; Suto, A | 1 |
1 trial(s) available for kt 6149 and Carcinoma
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion.
Topics: Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drugs, Investigational; Female; Humans; Infusions, Intravenous; Lung; Male; Middle Aged; Mitomycin; Mitomycins; Ovarian Neoplasms | 1995 |
1 other study(ies) available for kt 6149 and Carcinoma
| Article | Year |
|---|---|
Antitumor activity of 7-N-(2-((2-(gamma-L-glutamylamino) ethyl) dithio) ethyl) mitomycin C (KW2149) against human tumor xenografts serially transplanted into nude mice.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Intraductal, Noninfiltrating; Dose-Response Relationship, Drug; Humans; Injections, Intraperitoneal; Injections, Intravenous; Male; Mice; Mice, Inbred A; Mice, Inbred BALB C; Mice, Nude; Mitomycin; Mitomycins; Neoplasm Transplantation; Random Allocation; Transplantation, Heterologous | 1989 |